Modalis gains foundational CRISPR IP access

By The Science Advisory Board staff writers

April 3, 2020 -- Modalis Therapeutics has licensed intellectual property (IP) from CRISPR-related gene-editing company Editas Medicine.

Through the agreement, Modalis will use CRISPR-Guide Nucleotide Directed Modulation (CRISPR-GNDM) technology to create gene therapies for patients with genetic disorders. Financial terms of the agreement were not disclosed.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.